STOCK TITAN

Cognition Therapeutics Inc - CGTX STOCK NEWS

Welcome to our dedicated news page for Cognition Therapeutics (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cognition Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cognition Therapeutics's position in the market.

Rhea-AI Summary
Cognition Therapeutics hosted a virtual KOL event featuring expert clinicians and researchers discussing the need for new Alzheimer's disease treatments. They highlighted the importance of removing toxic oligomers, the limitations of current therapies, and the potential of CT1812 in restoring cognitive function. CT1812 is in Phase 2 trials with promising preliminary results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss recent corporate achievements and upcoming clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
conferences
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) to host a virtual KOL event to discuss CT1812, a potential drug for Alzheimer's disease treatment. Experts to provide insights on the current treatment landscape and ongoing clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) reported financial results for Q4 and full year 2023, highlighting milestones achieved in clinical trials for Alzheimer's and other neurodegenerative disorders. The company raised $10.4 million in a public offering, extending cash runway through May 2025. Key upcoming milestones include topline results from SHINE and SHIMMER studies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) to release financial results for Q4 and full year 2023 on March 26, 2024. The company aims to treat neurodegenerative disorders through regulating cellular damage response pathways. A conference call and live webcast will provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
conferences earnings
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) successfully closed a public offering of 6,571,428 shares of common stock at $1.75 per share, generating approximately $11.5 million in gross proceeds. The net proceeds will be used for research, clinical development, and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) announces a public offering of 6,571,428 shares of common stock at $1.75 per share, with gross proceeds expected to be $11.5 million. The offering aims to fund research, development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) has announced a public offering of its common stock, with an option for additional shares. The offering is subject to market conditions and may vary in size and terms. Titan Partners Group is the sole book-running manager for the offering. The company is utilizing an effective shelf registration statement with the SEC for this purpose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
-
Rhea-AI Summary
Cognition Therapeutics, Inc. presents proteomic and correlation analyses results at the AD/PD™ 2024 Conference. The studies focus on CT1812's impact on neurodegenerative disorders, particularly Alzheimer's disease, showcasing potential biomarkers and treatment effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
none
Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) announced that its president and CEO will present at the TD Cowen 44th Annual Health Care Conference to discuss the company's pipeline progress and recent achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
Cognition Therapeutics Inc

Nasdaq:CGTX

CGTX Rankings

CGTX Stock Data

76.44M
32.88M
6.5%
34.19%
0.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Purchase

About CGTX

cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.